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probably a common finding during normal every‑
day physical activity. In particular, we suspect that 
elevated hs ‑TnI levels (the high ‑sensitivity meth‑
od being particularly useful) are quite common 
during the daily activities of patients with HCM 
(even on pharmacotherapy). However, this phe‑
nomenon may be underdiagnosed or complete‑
ly unrecognized. Therefore, we decided to inves‑
tigate the presence of and potential mechanism 
underlying the increased hs ‑TnI levels in relation 
to findings on Holter monitoring.
Patients and methods Consecutive patients with 
HCM, treated and monitored at our clinic, were 
recruited to the study. Most patients received 
pharmacotherapy (TABLE 1) and underwent regu‑
lar medical check ‑ups as part of ambulatory care.
The  exclusion criteria were as follows: ST‑
‑segment or non ‑ST ‑segment elevation myocar‑
dial infarction (recent or previous), significant 
coronary stenosis on coronary angiography, or 
renal failure. The final sample included 32 pa‑
tients with HCM (mean [SD] age, 40 [11] years; 
20 men and 12 women).
According to the study protocol, echocardiog‑
raphy was performed first. Immediately after the 
echocardiography, a 24 ‑hour ECG test was start‑
ed to assess possible tachycardia episodes as a po‑
tential trigger of hs ‑TnI release. Moreover, we 
searched for possible episodes of nonsustained 
ventricular tachycardia (NSVT, a risk factor for 
sudden cardiac death according to the European 
Society of Cardiology and American Heart Asso‑
ciation / American College of Cardiology guide‑
lines) as a potential result of ischemia detected 
by hs ‑TnI release. The hs ‑TnI level was assessed 
Introduction High ‑sensitive troponin I (hs ‑TnI), 
an ultraprecise biomarker for the detection of 
myocardial ischemia, has been investigated in pa‑
tients with hypertrophic cardiomyopathy (HCM) 
in several studies.1-4 However, troponin levels 
were measured only at a resting state and were 
not synchronized in time with ambulatory elec‑
trocardiography (ECG) monitoring (Holter mon‑
itoring). So far, no studies have used the follow‑
ing protocol: 24 ‑hour Holter monitoring first and 
then the measurement of hs ‑TnI (the biomarker 
level has a close temporal relationship with find‑
ings on Holter monitoring). This protocol seems 
to be reasonable because hs ‑TnI levels may be 
both associated with increased heart rate (poten‑
tial cause of myocardial ischemia) and be a poten‑
tial cause of life ‑threatening ventricular arrhyth‑
mias occurring during the previous 24 hours.
As regards the dynamic stress test (under nat‑
ural conditions and related to a single episode of 
rapidly increased heart rate) in adults with HCM, 
there have been only 2 reports of troponin mea‑
surement (without the use of high ‑sensitivity 
method): one taken after an episode of rapid su‑
praventricular tachycardia in a natural every‑
day situation,5 and the other after a physician‑
‑controlled exercise stress test.6 The exercise stress 
test was performed in a small group of 7 patients, 
5 of whom revealed elevated troponin levels af‑
ter physical exercise, while in the repeated con‑
trol exercise test after β ‑blocker use, troponin re‑
lease was consistently diminished.6
There are no unequivocal data regarding the he‑
modynamic mechanism of myocardial ischemia 
diagnosed with hs ‑TnI release in HCM. An el‑
evated troponin level in patients with HCM is 
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relationship, myocardial ischemia may be associ‑
ated with NSVT in patients with HCM. In previ‑
ous experimental studies in patients in a resting 
supine position, ischemia was provoked by tachy‑
cardia, that is, rapid atrial pacing.7,8 In those stud‑
ies, the marker of myocardial ischemia was lac‑
tate metabolism (myocardial lactate extraction in‑
dicated the difference between arterial and great 
cardiac vein lactate contents). The negative differ‑
ence was defined as lactate production and pre‑
cisely indicated myocardial ischemia.
In patients with HCM,7 the transmural coro‑
nary flow reserve was exhausted at a heart rate of 
130 bpm. The higher heart rate resulted in a more 
severe metabolic evidence of ischemia (lactate 
production instead of consumption), and all pa‑
tients experienced chest pain. At a heart rate of 
150 bpm, most patients demonstrated an actu‑
al decline in the coronary flow, which correlat‑
ed with an increase in the left ventricular filling 
pressures and more severe metabolic evidence 
of ischemia.7
In a study by Cannon et al,8 up to 73% of pa‑
tients with HCM with reversible thallium ‑201 
(201Tl) abnormalities during exercise showed meta‑
bolic evidence of myocardial ischemia during rap‑
id atrial pacing (myocardial lactate extraction of 
0 mmol/l or less); 31% of the patients with nor‑
mal 201Tl scans showed myocardial ischemia (de‑
tected by metabolic measurement).
In a study by Ogata et al,9 assessing both in‑
vasive lactate measurement and noninvasive ex‑
ercise test, patients with HCM were shown to be 
at increased risk of myocardial ischemia during 
exercise, despite having normal results of coro‑
nary arteriograms but with pacing ‑induced ab‑
normal lactate metabolism.
Currently, hs ‑Tn in blood sample obtained from 
the peripheral vein is the best marker of isch‑
emia. Even in apical HCM with a relatively small 
left ventricular mass, an episode of supraven‑
tricular tachycardia with 180 bpm provoked tro‑
ponin release.5 Pop et al,6 in a study on patients 
with HCM and no abnormalities on coronary an‑
giogram, revealed that increased troponin release 
may be present before exercise and is temporarily 
enhanced on exertion and significantly decreased 
after the administration of a β ‑blocker.
In a recent study on HCM,10 mortality was pre‑
dicted using criteria for detecting ischemia on 
stress echocardiography. The authors concluded 
that stress echocardiography has an important 
prognostic role in patients with HCM, with isch‑
emic endpoints showing a greater predictive ac‑
curacy than hemodynamic endpoints.10
Although several studies evaluated the role of 
hs ‑Tn in patients with HCM, the relationship be‑
tween Holter ECG parameters and troponin level 
(measured nearly at the same time but with an ad‑
equate delay for the first half of the Holter mon‑
itoring, that is, the daily phase) has not been in‑
vestigated so far.1-4 In a recent review by McCar‑
thy et al,11 the utility of troponin assessment in 
arrhythmic disease was shown only for the the 
immediately on completing the Holter test. Pa‑
tients were asked to maintain normal physical 
activity during the test. The study protocol was 
approved by a local institutional review board.
Statistical analysis Continuous variables were 
presented as mean (SD). Categorical variables 
were assessed using the Fisher exact test and ex‑
pressed as numbers (percentages). Correlations 
between hs ‑TnI levels and ECG parameters were 
assessed using the Pearson correlation coeffi‑
cient. A P value of less than 0.05 was considered 
significant.
Results Baseline characteristics of the patients 
are presented in TABLE 1. Hs ‑TnI release was de‑
tected in all patients (range, 1.5–38 571 ng/l). 
Increased levels were revealed for 16 patients 
(troponin ‑positive group), and “normal ‑low” 
levels, in 16 patients (troponin ‑negative group). 
The hs ‑TnI level was correlated with the maxi‑
mum heart rate (stronger correlation: r = 0.69, 
P <0.01) and the mean heart rate (weaker corre‑
lation: r = 0.41, P <0.05). There was no correla‑
tion between the hs ‑TnI level and the minimum 
heart rate (r = 0.21, P = 0.39). The mean (SD) 
maximum heart rate and the mean (SD) heart 
rate were higher in the troponin ‑positive group 
than in the troponin ‑negative group: 139 (9) bpm 
vs 125 (8) bpm and 79 (8) bpm vs 69 (7), respec‑
tively (P <0.05 for both comparisons). NSVT 
episodes were more common in the troponin‑
‑positive group than in the troponin ‑negative 
group (75% vs 24%; P <0.03).
Discussion Our study suggests a potential risk of 
myocardial ischemia provoked by exercise ‑induced 
or spontaneous tachycardia. Regarding the causal 
TABLE 1 Baseline characteristics of the patients
Ejection fraction, %, mean (SD) 60.9 (13.2)
Maximum LV thickness, mm, mean (SD) 21.7 (4.8)
Resting LVOT gradient, mm Hg, mean (SD) 18.31 (17.23)
Resting LVOT gradient, >30 mm Hg, n (%) 7 (21.9)
Left atrial diameter, mm, mean (SD) 49.1 (10.7)
LV end ‑diastolic diameter, mm, mean (SD) 43.4 (8.8)
NYHA classa, mean (SD) 2.0 (0.71)
CCS classa, mean (SD) 1.3 (0.5)
Syncopea, n (%) 0 (0%)
NSVTa, n (%) 12 (37.5)
Sudden death in family history, n (%) 11 (34)
Creatinine, µg/l, mean (SD) 87.1 (16.5)
Drugs with negative chronotropic 
propertiesa, n (%)





a Parameters recorded during Holter monitoring in the current study
Abbreviations: CCS, Canadian Cardiovascular Society; LVOT, left ventricular outflow 
tract; LV, left ventricular; NSVT, nonsustained ventricular tachycardia; NYHA, New York 
Heart Association
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initial stage, but it was proposed as a valuable 
screening marker for patients with HCM at high 
risk of sudden cardiac death.
Regular training exercise has recently been rec‑
ommended for patients with HCM.12 In our opin‑
ion, based on the association between tachycardia 
or tachyarrhythmia (NSVT) and elevated troponin 
levels in patients with HCM, we suggest that any 
exercise stress test in these patients (performed 
either for training or diagnostic purposes) should 
be controlled by troponin level measurements 6 
and 12 hours after the test.
Our study has several limitations. First, 
the current pharmacological treatment was main‑
tained, and particularly β ‑blockers were not with‑
drawn. In different patients, 3 β ‑blockers were 
used: metoprolol, bisoprolol, and sotalol; there‑
fore, a comparison of the dose of β ‑blockers 
between the troponin ‑positive and troponin‑
‑negative groups was statistically impossible be‑
cause of the small number of patients in the 6 sub‑
groups: metoprolol TnI(+) vs metoprolol TnI(–), 
bisoprolol TnI(+) vs bisoprolol TnI(–), and so‑
talol TnI(+) vs sotalol TnI(+). In our pilot study, 
we aimed to make the first ‑ever observation on 
the correlation between hs ‑TnI release and find‑
ings on Holter monitoring. Our preliminary study 
showed that β ‑blocker withdrawal might not be 
safe in this group of patients, and in future stud‑
ies, we will attempt to increase the dose and use 
only one type of a β ‑blocker to minimize an in‑
crease in heart rate and, consequently, decrease 
ischemia burden and the risk of troponin release.
We decided to measure hs ‑TnI levels only once 
because our pilot study was conducted in an out‑
patient setting. The optimal protocol, that is, a 
48 ‑hour profile of troponin measurement with 
the assessment of troponin during the ECG test 
and every 3 to 6 hours after the test, would re‑
quire the in ‑hospital setting and would be more 
costly. Moreover, only an outpatient ‑based study 
provides an opportunity to assess the heart rate 
during daily routine physical activity of patients.
In conclusion, our study showed that the ele‑
vated hs ‑TnI level correlated with an increased 
heart rate on Holter monitoring, especially with 
the maximum heart rate. Moreover, high hs ‑TnI 
levels were associated with the presence of NSVT. 
Moreover, 75% of the patients with positive tro‑
ponin were shown to have NSVT. Further re‑
search is needed to assess the protective role of 
β ‑blockers in tachycardia ‑related troponin release.
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